8-K: RenovoRx Reports Q3 2025 Growth, $900K YTD Revenue

RenovoRx announced its third quarter 2025 financial results, reporting approximately $900,000 in year-to-date revenue and $10 million in cash, alongside updates on RenovoCath commercialization and Phase III TIGeR-PaC trial progress.

Summary

• Year-to-date revenue through Q3 2025 reached approximately $900,000, with Q3 revenue at approximately $266,000.
• Cash and cash equivalents stood at $10.0 million as of September 30, 2025, which is believed to be sufficient to fund ongoing commercialization and Phase III TIGeR-PaC trial enrollment completion in early 2026.
• The number of cancer centers approved to purchase RenovoCath expanded from 5 at the start of 2025 to 14 as of November 7, 2025, with repeat orders increasing.
• Product quotes have been delivered to 10 additional leading centers, bringing the total to 24 centers formally requesting quotes for RenovoCath.
• The Phase III TIGeR-PaC clinical trial remains on track for enrollment completion in early 2026 and final data readout in 2027.
• A new post-marketing registry study for RenovoCath was successfully launched, with the first patient procedure initiated in September 2025.
• Net loss for Q3 2025 was $2.9 million, compared to $2.5 million for Q3 2024, while year-to-date net loss was $8.2 million compared to $5.9 million for the same period in 2024.
• Selling, general, and administrative expenses increased to $1.7 million for Q3 2025 from $1.2 million in Q3 2024, reflecting commercial expansion.

Sentiment

Score: 7

Explanation: The company reported strong progress in commercial adoption of RenovoCath, expanding its customer base and generating repeat orders. Clinical trials are on track, and the cash position is deemed sufficient for near-term milestones. While the net loss increased, it's consistent with a growth-stage company investing in its future. The outlook for revenue growth in 2026 is positive, indicating a favorable trajectory despite current losses.

Positives

• Year-to-date revenue grew to approximately $900,000, demonstrating early commercial traction for RenovoCath.
• The customer base for RenovoCath expanded significantly from 5 to 14 approved cancer centers, including high-volume NCI-designated centers, with increasing repeat purchase orders.
• The Phase III TIGeR-PaC clinical trial is on track for enrollment completion in early 2026 and final data readout in 2027.
• Successfully launched a new post-marketing registry study to gather real-world evidence on RenovoCath's use.
• Cash and cash equivalents increased to $10.0 million, which is projected to fund operations through key milestones in early 2026.
• Strengthened the commercial team with the hiring of a Senior Director of Sales & Market Development and two regional sales managers, with plans for a marketing director.
• The estimated initial total addressable market for RenovoCath as a stand-alone device is approximately $400 million peak annual U.S. sales, with long-term potential in the billions.

Negatives

• Net loss increased to $2.9 million for Q3 2025 from $2.5 million in Q3 2024.
• Year-to-date net loss also increased to $8.2 million from $5.9 million in the prior year period.
• Selling, general, and administrative expenses rose to $1.7 million for Q3 2025, up from $1.2 million in the prior year, indicating increased operational costs.

Risks

• Commercial opportunities for the TAMP technology may not lead to viable, revenue-generating operations.
• Circumstances could adversely impact the ability to efficiently utilize cash resources or raise additional funding.
• Uncertainty regarding the timing, progress, and potential results of preclinical studies, clinical trials, and research programs.
• Interim results from clinical trials may not be predictive of final outcomes, and trials may not demonstrate sufficient safety and efficacy for regulatory approval.
• Regulatory authorities may disagree with the interpretation of data, research, and clinical development plans or timelines.
• Uncertainty regarding future potential regulatory milestones for product candidates.
• Challenges in expanding the therapy platform to build a pipeline of product candidates.
• Difficulties in advancing product candidates into, and successfully completing, clinical trials.
• Uncertainty regarding the timing or likelihood of regulatory filings and approvals.
• Estimates of patient populations for targeted diseases and clinical trial enrollment may be inaccurate.
• The commercialization potential of product candidates, if approved, may not be realized.
• Challenges in successfully manufacturing and supplying product candidates for clinical trials and commercial use.
• Future strategic arrangements and/or collaborations may not materialize or provide expected benefits.
• Estimates regarding expenses, future revenue, capital requirements, and needs for additional financing, as well as the ability to obtain additional capital, may be incorrect.
• The sufficiency of existing cash and cash equivalents to fund future operating expenses and capital expenditure requirements is subject to change.
• Difficulty in retaining key personnel and identifying, hiring, and retaining additional qualified personnel.
• Challenges in the implementation of strategic plans for the business and product candidates.
• Limitations on the scope of protection for intellectual property rights.
• Inability to contract with third-party suppliers and manufacturers or their inadequate performance.
• Uncertainty regarding the pricing, coverage, and reimbursement of product candidates, if approved.
• Adverse developments relating to competitors and the industry.

Future Outlook

RenovoRx expects revenue to grow in 2026 and continue to offset cash burn. The Phase III TIGeR-PaC trial is anticipated to complete enrollment in early 2026 with final data readout in 2027. The company plans to add a marketing director by the end of the year to drive additional physician engagement. Long-term, the TAMP platform has several-billion-dollar potential as it expands into additional solid tumor indications beyond the initial $400 million peak annual U.S. sales opportunity for RenovoCath as a stand-alone device.

Management Comments

• "We continue to make strong progress both in our commercial and clinical activities."
• "On the commercial side, we are encouraged by the continued RenovoCath clinical adoption we are seeing in the field."
• "Year-to-date revenue, through the end of the third quarter, was approximately $900,000, reflecting the growing clinical need and market demand for targeted drug-delivery solutions."
• "Since organically launching commercial sales less than a year ago, we have expanded from five centers at the start of 2025 to 14 leading cancer centers now approved to purchase RenovoCath, including several that have already made repeat orders."
• "With the recent hiring of Philip Stocton as Senior Director of Sales & Market Development and two regional sales managers, we are building the foundation for sustained growth while maintaining a lean operating structure and prudent capital deployment philosophy."
• "Our team remains laser-focused on strategic, data-driven expansion and is encouraged by the increasing physician-to-physician advocacy for our TAMP (Trans-Arterial Micro-Perfusion) platform as we continue to position RenovoRx for long-term success."
• "On the clinical side, we continue to advance our Phase III TIGeR-PaC trial towards enrollment completion in early 2026 and final data readout in 2027, and we've successfully launched a new post-marketing registry study from which we expect to garner real-world evidence on the use of the RenovoCath device."

Industry Context

RenovoRx operates in the highly competitive and innovative life sciences sector, specifically focusing on targeted oncology therapies and drug-delivery devices. The company's TAMP platform and RenovoCath device address a critical industry need for more precise drug delivery to minimize systemic toxicity and improve patient quality of life, particularly for challenging cancers like pancreatic cancer. This aligns with broader industry trends towards personalized medicine and less invasive, more targeted treatments. The expansion into NCI-designated cancer centers and community hospitals reflects a standard commercialization strategy for novel medical devices, aiming to integrate new technologies into established clinical practices.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess RenovoRx's performance against global industry benchmarks. The focus is on internal progress and milestones.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for long-term value creation through commercial growth of RenovoCath and successful clinical development of the TAMP platform, but current net losses indicate ongoing investment phase.
• Patients: Improved outcomes and quality of life through more targeted and tolerable cancer treatments, particularly for solid tumors like pancreatic cancer.
• Physicians/Healthcare Providers: Increased access to a novel, FDA-cleared drug-delivery device (RenovoCath) and TAMP technology, supported by growing physician-to-physician advocacy and clinical adoption.
• Employees: Expansion of the commercial team with new hires and planned additions, indicating growth opportunities within the company.
• Creditors: The company's cash position of $10.0 million is deemed sufficient to fund operations through key milestones in early 2026, providing some financial stability.

Next Steps

• Continue to advance the Phase III TIGeR-PaC trial towards enrollment completion in early 2026.
• Continue progress in the post-market registry study to garner real-world evidence on RenovoCath.
• Add a marketing director by the end of the year to drive additional physician engagement.
• Collect valuable market insights from the first year of commercialization to inform strategy and execution plans heading into 2026.
• Actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner.

Key Dates

Recommendation

RenovoRx is demonstrating early but promising commercial traction with its RenovoCath device, expanding its customer base and generating repeat orders. The Phase III TIGeR-PaC trial is on track for enrollment completion in early 2026, and a new post-marketing registry study has been launched. While revenue is growing, the company continues to operate at a net loss, and significant profitability is still some time away. The current cash position is deemed sufficient for key near-term milestones, which is positive. However, the company is still in a high-growth, high-risk phase, balancing commercialization with clinical development. The long-term potential is significant if the TAMP platform expands, but this is speculative. Therefore, a "Hold" recommendation is appropriate for investors to monitor continued commercial adoption and clinical trial progress without taking on excessive new risk at this stage.

Keywords

RenovoRx, RNXT, RenovoCath, TAMP therapy, targeted oncology, drug delivery device, pancreatic cancer, Phase III clinical trial, TIGeR-PaC, Q3 2025 earnings, medical device, biotechnology, cancer treatment, FDA-cleared device